Healthcare

Breast Cancer Market Size To Cross USD 70.51 Bn By 2030

The global breast cancer market size accounted for US$ 31.89  Bn in 2022 and is projected to reach around USD 70.51 Bn by 2030, growing at a CAGR of 10.43% from 2022 to 2030.

Breast Cancer Market Size 2022 To 2030

Report Summary

The global breast cancer  market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the breast cancer  market across the globe.

A comprehensive estimate on the breast cancer  market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of breast cancer  during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2396

Breast Cancer Market Report Scope 

Report Coverage Details
Market Size in 2022 USD 31.89 Billion
Market Size by 2030 USD 70.51 Billion
Growth Rate from 2022 to 2030 CAGR of 10.43%
Largest Market North America
Second Largest Market Asia Pacific
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered
  • By Therapy
  • By Cancer Type
  • By Distribution Channel

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized breast cancer  market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read:  Chemistry 4.0 Market Size, Share, Report 2030

Breast Cancer Market Players

The report includes the profiles of key breast cancer  market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Merck & Co
  • Bristol Myers Squiib
  • Kyowa Kirin
  • Eisai Co.Ltd
  • Sanofi
  • Pfizer Inc
  • AstraZeneca
  • Novartis AG
  • Eli Lilly and Company
  • Genentech
  • Mylan Laboratories
  • Celltrion
  • Fresenius Kabi
  • Baxter Healthcare Corporation
  • Halozyme Inc
  • GlaxoSmithKline

Market Segmentation

By Therapy

  • Targeted Therapy
    • Abemaciclib
    • Adotrastuzumab Emtansine
    • Everolimus
    • Trastuzumab
    • Ribociclib
    • Palbocicib
    • Pertuzumab
    • Olaparib
    • Others
  • Hormonal Therapy
    • Selective Estrogen Receptor Modulators
    • Aromatase Inhibitors
    • Estrogen Receptor Downregulators
    • Chemotherapy ( Epothiones, Taxanes, Alkylating agents, Anthracyclines, Anti-metabolites)
    • Immunotherapy
  • Surgery and radiation therapy
  • Biologic therapy

By Cancer Type

  • Hormone Receptor
  • HER2+

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Breast Cancer Market 

5.1. COVID-19 Landscape: Breast Cancer Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Breast Cancer Market, By Therapy

8.1. Breast Cancer Market, by Therapy, 2022-2030

8.1.1 Targeted Therapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Hormonal Therapy

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Surgery and radiation therapy

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Biologic therapy

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Breast Cancer Market, By Cancer Type

9.1. Breast Cancer Market, by Cancer Type, 2022-2030

9.1.1. Hormone Receptor

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. HER2+

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Breast Cancer Market, By Distribution Channel 

10.1. Breast Cancer Market, by Distribution Channel, 2022-2030

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Breast Cancer Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.1.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Therapy (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Cancer Type (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 12. Company Profiles

12.1. Merck & Co

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bristol Myers Squiib

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Kyowa Kirin

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Eisai Co.Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Sanofi

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Pfizer Inc

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. AstraZeneca

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Novartis AG

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Eli Lilly and Company

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Genentech

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com

Show More

Related Articles

Back to top button